PharmaGraphX

Log in Get Started

Methylphenidate

Ritalin, Concerta, Metadate, Daytrana, Quillivant, Aptensio, QuilliChew, Cotempla, Relexxii, Adhansia, Jornay, Methylin

CNS Stimulant • Dopamine/norepinephrine reuptake inhibitor

Premium

Half-life

2-4 hours (IR); 3.5 hours (ER)

Protein Binding

15%

Metabolized By

CES1A1

External

Drugs.com

Boxed warning

High potential for abuse and dependence
Sudden death reported in patients with structural cardiac abnormalities

Clinical alerts

Boxed warning

2 boxed warnings

Mechanism of action

Blocks dopamine and norepinephrine reuptake, increasing their synaptic concentrations

Recorded indications

From the drug index — may include conditions studied rather than approved indications

·Nicotine Dependence
·Velocardiofacial Syndrome
·Williams Syndrome
·Fragile X Syndrome
·ADHD

Interactions

No curated interaction pairs are recorded for Methylphenidate. This is not a statement that none exist — check a full interaction reference before combining.

Common adverse effects

Decreased appetite
Insomnia
Headache
Abdominal pain
Tachycardia

Food, alcohol & herbal

Food

High-fat meal may delay absorption of ER formulations

Alcohol · major

May cause rapid release of ER formulations; CNS effects

Herbal

Caffeine (moderate) — Additive stimulant effects

Pharmacokinetics

Half-life: 2-4 hours (IR); 3.5 hours (ER)
Protein binding: 15%
Metabolised by: CES1A1

Pregnancy & lactation

Not recorded for Methylphenidate. Absence here means this database does not hold a category — not that the drug is safe in pregnancy or breastfeeding.

Sources

Assembled from: drug index, curated drug database.

Not a substitute for clinical judgement

Methylphenidate

Ritalin, Concerta, Metadate, Daytrana, Quillivant, Aptensio, QuilliChew, Cotempla, Relexxii, Adhansia, Jornay, Methylin

CNS Stimulant • Dopamine/norepinephrine reuptake inhibitor

Premium

Half-life

2-4 hours (IR); 3.5 hours (ER)

Protein Binding

15%

Metabolized By

CES1A1

External

Drugs.com

Boxed warning

High potential for abuse and dependence
Sudden death reported in patients with structural cardiac abnormalities

Clinical alerts

Boxed warning

2 boxed warnings

Mechanism of action

Blocks dopamine and norepinephrine reuptake, increasing their synaptic concentrations

Recorded indications

From the drug index — may include conditions studied rather than approved indications

·Nicotine Dependence
·Velocardiofacial Syndrome
·Williams Syndrome
·Fragile X Syndrome
·ADHD

Interactions

No curated interaction pairs are recorded for Methylphenidate. This is not a statement that none exist — check a full interaction reference before combining.

Common adverse effects

Decreased appetite
Insomnia
Headache
Abdominal pain
Tachycardia

Food, alcohol & herbal

Food

High-fat meal may delay absorption of ER formulations

Alcohol · major

May cause rapid release of ER formulations; CNS effects

Herbal

Caffeine (moderate) — Additive stimulant effects

Pharmacokinetics

Half-life: 2-4 hours (IR); 3.5 hours (ER)
Protein binding: 15%
Metabolised by: CES1A1

Pregnancy & lactation

Not recorded for Methylphenidate. Absence here means this database does not hold a category — not that the drug is safe in pregnancy or breastfeeding.

Sources

Assembled from: drug index, curated drug database.

Not a substitute for clinical judgement